ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - tetanus toxoid >= 40 iu/dose; bordetella pertussis toxoid (pt) 25 µg/dose; bordetella pertussis filamentous hemagglutinin (fha) 25 µg/dose; bordetella pertussis pertactin 8 µg/dose; diphtheria toxoid (dt) >= 30 iu/dose - suspension for injection in pre-filled syringe - diphteria antigen, adsorbed; tetanus toxoid adsorbed; bordetella pertussis - pertussis, purified antigen, combinations with toxoids

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - diphtheria toxoid (dt) >= 30 iu/dose; poliovirus type 2 (inactivated) 8 d-antigen u/0,5 ml; bordetella pertussis filamentous hemagglutinin (fha) 25 µg/dose; poliovirus type 1 (inactivated) 40 d-antigen u/0,5 ml; tetanus toxoid >= 40 iu/dose; bordetella pertussis toxoid (pt) 25 µg/dose; bordetella pertussis pertactin 8 µg/dose; poliovirus type 3 (inactivated) 32 d-antigen u/0,5 ml - suspension for injection - diphteria antigen, adsorbed; poliomyelitis virus; tetanus toxoid adsorbed; bordetella pertussis antigen, proteins - diphtheria-pertussis-poliomyelitis-tetanus

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit); pertactin 2.5ug;  ; pertussis filamentous haemagglutinin 8ug;  ; pertussis toxoid, adsorbed 8ug;  ; tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit); diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit); pertactin 2.5ug; pertussis filamentous haemagglutinin 8ug; pertussis toxoid, adsorbed 8ug; tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit) pertactin 2.5ug   pertussis filamentous haemagglutinin 8ug   pertussis toxoid, adsorbed 8ug   tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit) excipient: aluminium hydroxide aluminium phosphate formaldehyde glycine phenoxyethanol polysorbate 80 sodium chloride water for injection active: diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit) pertactin 2.5ug pertussis filamentous haemagglutinin 8ug pertussis toxoid, adsorbed 8ug tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit) excipient: aluminium hydroxide aluminium phosphate sodium chloride water for injection - boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged four years and older.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 2 [iu] (2.5lfu); pertactin 2.5ug;  ; pertussis filamentous haemagglutinin 8ug;  ; pertussis toxoid, adsorbed 8ug;  ; polio virus type 1 40 dagu;  ; polio virus type 2 8 dagu;  ; polio virus type 3 32 dagu;  ; tetanus toxoid 20 [iu] (5lfu) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 2 [iu] (2.5lfu) pertactin 2.5ug   pertussis filamentous haemagglutinin 8ug   pertussis toxoid, adsorbed 8ug   polio virus type 1 40 dagu   polio virus type 2 8 dagu   polio virus type 3 32 dagu   tetanus toxoid 20 [iu] (5lfu) excipient: aluminium medium 199 sodium chloride water for injection - boostrix®-ipv is indicated for booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis of individuals from the age of four years onwards. boostrix®-ipv is not intended for primary immunisation.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - neisseria meningitidis group c polysaccharide 10ug (polysaccharide antigen from strain c11, conjugated to tetanus toxoid) - suspension for injection - 10 mcg/0.5ml - active: neisseria meningitidis group c polysaccharide 10ug (polysaccharide antigen from strain c11, conjugated to tetanus toxoid) excipient: aluminium hydroxide sodium chloride tetanus toxoid water for injection - active immunisation of children from 8 weeks of age, adolescents and adults for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - pneumococcal polysaccharide serotype 1 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 14 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 18c 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 19a 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 19f 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 23f 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 3 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 4 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 5 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 6a 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 6b 4.4ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 7f 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 9v 2.2ug (conjugated with diphtheria crm 197 protein) - suspension for injection - 0.5 ml - active: pneumococcal polysaccharide serotype 1 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 14 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 18c 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 19a 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 19f 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 23f 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 3 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 4 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 5 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 6a 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 6b 4.4ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 7f 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 9v 2.2ug (conjugated with diphtheria crm 197 protein) excipient: aluminium phosphate polysorbate 80 sodium chloride succinic acid water for injection - active immunisation for the prevention of pneumococcal disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f in adults and children aged more than 6 weeks of age. the use of prevenar 13 should be guided by official recommendations.

イスラエル - 英語 - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); pertactin (prn or 69 kda omp); pertussis toxoid (pt); tetanus toxoid - suspension for injection - diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid (pt) 8 mcg / 0.5 ml; pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml - tetanus toxoid, combinations with diphtheria toxoid - tetanus toxoid, combinations with diphtheria toxoid - for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards.the administration of boostrix should be based on official recommendations

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pneumococcal purified capsular polysaccharides, quantity: 2.2 microgram; pneumococcal purified capsular polysaccharides, quantity: 4.4 microgram - injection, suspension - excipient ingredients: aluminium phosphate; water for injections; polysorbate 80; diphtheria crm197 protein; succinic acid; sodium chloride - active immunisation for the prevention of pneumococcal disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f in adults and children aged more than 6 weeks of age. the use of prevenar 13 should be guided by official recommendations.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - diphtheria toxoid tetanus toxoid pertussis toxoid filamentous haemagglutinin (fha) pertactin polio virus type 1 inactivated polio virus type 2 inactivated polio virus type 3 inactivated haemophilus influenzae type b capsular polysaccharide (prp) and tetanus toxoid tetanus vaccine adsorbed - %v/v

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

tetanus toxoid; diphtheria toxoid; polyribose ribitol phosphate - haemophilus influenzae type b; poliovirus; pertactin; pertussis toxoid; hepatitis b surface antigen recombinant; pertussis filamentous haemagglutinin -